Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy

TOP - May 2013, Vol 6, No 2 published on June 3, 2013 in Breast Cancer

Studies have suggested that musculoskeletal toxicity associated with aromatase inhibitor therapy can lead to noncompliance in up to one-third of women with breast cancer. A large, single-center, cohort study at a regional cancer center found that the rate of musculoskeletal toxicity in women with early breast cancer treated with endocrine therapy was 64%. Patients taking aromatase inhibitors experienced almost twice the frequency of musculoskeletal toxicity as those taking tamoxifen: 64% versus 36%, respectively. These findings are similar to a report in the literature, showing that 61% of women receiving aromatase inhibitors experienced musculoskeletal toxicity in clinical trials.1 The findings were presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.2

“Despite the high incidence of musculoskeletal toxicity observed in patients taking aromatase inhibitors, the majority continued treatment, with only 22.9% of women discontinuing therapy for this reason,” stated lead author Susan F. Dent, MD, of the Ottawa Hospital Cancer Centre, the University of Ottawa, Ontario, Canada. This is also similar to the report in the literature, where Gaillard and colleagues found that 20% discontinued aromatase inhibitor therapy due to musculoskeletal toxicity in clinical trials.

The study was based on a retrospective chart review at the Ottawa Hospital Cancer Centre between January 1999 and December 2006. The population included 626 postmenopausal women with hormone receptor–positive early breast cancer treated with endocrine therapy, including at least 1 aromatase inhibitor.

Mean age was 59 years. Median follow-up was 98 months, and median duration of treatment with an aromatase inhibitor was 59 months. The women had a total of 1117 prescriptions that included letrozole, anastrozole, exemestane, and tamoxifen. Musculoskeletal toxicity developed in 68% of those taking letrozole, 47.6% of those taking exemestane, 63.9% of those taking anastrozole, and 36% of those taking tamoxifen. Median time to developing musculoskeletal toxicity was 21 months, 9 months, 23 months, and 23 months, respectively.

The most common musculoskeletal toxicities were arthralgias (41%), myalgias (25%), osteoporosis/osteopenia (23%), and arthritis (19%). Treatment was discontinued for these toxicities significantly more often with any aromastase inhibitor than with tamoxifen: 14.6% versus 4.8%, respectively (P <.0001). Treatment strategies for musculoskeletal toxicity did not significantly impact adherence to therapy, except in the case of exemestane. Among the group treated with exemestane, adherence rate with no intervention was 33% and adherence increased to 80% with musculoskeletal toxicity intervention, including mediation and physiotherapy (P <.0001). Longer exposure to any endocrine therapy did not appear to increase the rate of musculoskeletal toxicity. Among this group of women, 51% completed 5 years of endocrine therapy as prescribed.

1. Gaillard S, Stearns V. Aromatase inhibitor associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011;13(2):205.
2. Dent SF, Campbell MM, Crawley FL, et al. The impact of musculoskeletal toxicity on adherence to endocrine therapy in women with early stage breast cancer—observations in a non-trial setting. Presented at: 2012 CTRC-AACR San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Poster P1-05-06.

Related Items
FDA Updates Mammography Regulations in MQSA Final Rule
TOP - May 2023 Vol 16, No 3 published on May 15, 2023 in Breast Cancer
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in Breast Cancer, SABCS
Factors Associated with Greater Risk for Abemaciclib Discontinuation in Patients with Early-Stage Breast Cancer
William King
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Trastuzumab Deruxtecan Represents New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
William King
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Breast Cancer
Neoadjuvant Nivolumab plus Chemotherapy May Be a New Standard of Care in Resectable NSCLC
Phoebe Starr
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Lung Cancer
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS, Breast Cancer
Trastuzumab Deruxtecan Beats Trastuzumab Emtansine as Second-Line Therapy for HER2-Positive Metastatic Breast Cancer
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS, Breast Cancer
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Last modified: July 22, 2021